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Introduction
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathologic, and genetic levels. Approximately 75% of newly diagnosed tumors are non-muscle invasive (Ta, Tis, and T1); most of them recur and 15-20% progress to invade muscle. The remaining 25% of patients present with muscle-invasive tumors and have a 5-yr survival of <50% [1] [2] [3] . Fibroblast growth factor receptor 3 (FGFR3) is the most commonly mutated gene in UBC, with an overall frequency of 60% [4] [5] [6] . Mutations in Harvey rat sarcoma viral oncogene homolog (HRAS), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), Kirsten rat sarcoma viral oncogene homolog (KRAS), and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) are less frequent [6, 7] . FGFR3 mutations are associated with stage and grade and are very common in pTa and grade 1/2 tumors. This makes FGFR3 mutation analysis in voided urine a useful tool for diagnosing recurrent disease after a primary non-muscle-invasive bladder cancer (NMIBC) [8, 9] .
Telomerase increases telomere length at chromosome ends. This activity is crucial for proliferating cells: Without telomerase, chromosomes are shortened every cell-division cycle, leading to replicative senescence and genomic instability [10, 11] . Telomerase is active in stem cells but becomes downregulated in differentiated cells in somatic tissues. By contrast, it becomes reactivated in many tumors. Somatic hotspot mutations in the promoter of the gene coding for telomerase reverse transcriptase (TERT) catalytic subunit have recently been described in 71% of sporadic melanomas; germline mutations have also been reported in a melanoma kindred [12, 13] . The somatic mutations were mutually exclusive C-to-T transitions at nucleotides 1,295,228 (C228T) and 1,295,250 (C250T). These are the first hotspot somatic mutations reported in a gene promoter in human cancers and have been proposed to enhance TERT expression through the creation of novel binding sites for E-twenty-six (ETS)/ELK transcription factors [12, 13] . Nevertheless, direct proof for this mechanism is absent. Interestingly, Huang et al. reported the C228T mutation in three of three UBC cell lines [12] and, in a survey of different tumor types, TERT promoter mutations were also found in UBC, hepatocarcinoma, glioblastoma, oligodendroglioma, and myxoid liposarcomas, but not in breast, colorectal, and prostate cancers [14] . However, the number of bladder tumors analyzed was small and clinical or pathologic information was not available [14] .
In this paper, we investigate the frequency of TERT promoter mutations in two large series of UBC. In the first one, lacking outcome information, we assessed the relationship between TERT mutations and TERT messenger RNA (mRNA) expression; in the second, with patient follow-up, we assessed the relationship between mutations and outcome. Finally, we explored whether mutation detection in urine may be used to identify tumor recurrence.
2.
Materials and methods
Patient characteristics
A set of 111 patients with associated frozen tumor samples came from the Spanish Bladder Cancer/EPICURO Study [15, 16] histologically proven tumor. Table 2 shows the characteristics of patients included in the urine study. 
Cell lines
UBC cell lines (Supplemental Table 1 ) were cultured under standard conditions and used for DNA extraction when at 70-80% confluence. All cultures were Mycoplasma free; their identity was tested by analysis of known genetic mutations.
DNA isolation and mutation analyses
Tumor cell-containing regions were macrodissected from frozen blocks or 10 (13) 23 (16) 20 (15) Mut = mutant; NMIBC = non-muscle-invasive bladder cancer; TERT = telomerase reverse transcriptase; WT = wild type. * The C242T mutation was not assessable with the SNaPshot assay. PCR conditions can be provided on request to the authors. FGFR3 mutation assays were performed as described [8] .
For the TERT mutational analysis in the second patient group, we [reverse]), similar to the previously designed FGFR3 mutation assay [8] .
The PCR was followed by a single-nucleotide extension using probes annealing to the amplicon adjacent to the mutation site. Probe sequences (Fig. 1B) .
For urine DNA extraction and mutation analysis, cell pellets were washed twice with phosphate-buffered saline, after thawing, by centrifugation for 5 min at 6000 rpm (3000 g). DNA was extracted using the QiAamp Mini and Blood mini kit (Qiagen NV, Venlo, Netherlands)
according to the manufacturer's protocol. TERT mutational analysis was performed using the SNaPshot assay.
Reverse transcriptase-quantitative PCR (RT-qPCR) was used to assess TERT RNA expression (see Supplement).
Statistical and bioinformatics analyses
The Predictive Analytics Software v.19 (IBM Corp., Armonk, NY, USA) was used. Statistical differences were considered significant if p < 0.05. The chi-square and Fisher exact tests were used to determine the relationships between different variables. Statistical differences between groups were assessed using a nonparametric Wilcoxon test, as appropriate. The logrank test was used for survival analysis. In the NMIBC group, all outcomes 
Results

TERT promoter mutations in bladder cancer
We first analyzed the occurrence of mutations in UBC cell lines and tumors using Sanger sequencing of PCR products. Of 32 lines analyzed, 4 were wild type and 28 (87%) harbored the C228T (n= 25) or C250T (n = 3) mutations (Supplemental Table 1 ). The somatic nature of these mutations could not be evaluated due to lack of germline DNA. Among the 111 UBCs from Spain, covering the full spectrum of the localized disease, 78 were mutated (70%) ( Table 1 ). The most common mutation was C228T (n = 65), followed by C250T (n = 10); two additional rare mutations were C242T/C243T (n = 2) and C228A (n = 1). All mutations were mutually exclusive; their somatic nature was confirmed in 10 cases (Fig. 1A) . The C250T mutation was significantly less common in UBC than in melanoma ( p = 0.00003); the C228T/C229T mutation reported in melanoma was not found in UBC. TERT mutations were not associated with age, sex, or smoking. The frequency of TERT mutations was similar in low-risk NMIBC (TaG1 and We analyzed the two most frequent TERT mutations in an independent set of tumors from the Netherlands using a specifically designed SNaPshot assay; mutations were found to be mutually exclusive. A high mutation rate was confirmed in both NMIBC (147 of 184 [80%]) and MIBC (136 of 173 [79%]) (Fig. 1C) . To assess heterogeneity, we analyzed TERT mutations using the SNaPshot assay in multiple (median: 4; range: 2-5) regions of nine NMIBCs. We observed general consistency among the regions, suggesting a low level of intraindividual heterogeneity (Supplemental Table 2 ). These findings place TERT mutations as the most common genetic alteration in UBC [6, 7] and as an early event in urothelial carcinogenesis.
TERT mutations have been proposed to generate novel transcription factor binding sites leading to increased TERT expression [12, 13] . Mining the DNA-binding factor database JASPAR, we performed a comparative analysis of the wild-type and mutant sequences and found that the C228A mutation newly reported in this paper was also associated with an increased probability of binding to ELK1 (a member of the ETS oncogene family) and v-ets avian erythroblastosis virus E26 oncogene homolog 1 (ETS1), as the previously reported mutations. The analysis revealed additional transcription factors that could contribute to TERT overexpression as well some that showed mutation selectivity, such as v-rel avian reticuloendotheliosis viral oncogene homolog (REL) for C242T/C243T or GATA bind protein 2 (GATA2) for C228A (Supplemental Table 3 ). To assess the relationship between TERT mutations and mRNA levels, we analyzed 60 primary UBC samples using RT-qPCR. TERT mRNA levels were higher in TERT mutant tumors, but the difference was not statistically significant (Wilcoxon test p = 0.3). TERT mRNA levels were significantly higher in high-risk NMIBC and in MIBC than in low-risk NMIBC (Wilcoxon test p = 0.001) (Fig. 1D ).
TERT mutations and patient outcome
The set of tumors from the Netherlands was used to assess tumor prognostic value. Of 184 patients with NMIBC, 90 (49%) experienced progression to MIBC (Table 1) . There was no relationship between progression-free survival and the presence of mutations (log-rank test p = 0.984) (Supplemental Fig. 1 ). In the group of 173 patients with MIBC, 78 (45%) patients had local or distant progression and TERT mutation status was not associated with progression-free survival (log-rank test p = 0.160). Furthermore, 101 (58%) patients died during follow-up, including 65 (37%) who died of bladder cancer (Table 1) . Overall-and cancer-specific survival were not related to TERT mutations (log-rank tests p = 0.987 and p = 0.834) (Supplemental Fig. 1 ). Among patients with MIBC, 25 received adjuvant chemotherapy with curative intent; TERT mutations were not predictive for survival in this subgroup or the group without chemotherapy. for both combined (FGFR3 vs TERT, p = 0.0001). In the recurrence-free urine samples, a TERT mutation was detected in 58 of 218 cases, corresponding to a specificity of 73%, whereas the specificity for FGFR3 mutation was 90% (FGFR3 vs TERT, p < 0.0001).
Discussion
TERT promoter hotspot mutations constitute a new type of somatic genetic alterations in cancer. A recent survey in a wide range of tumors indicated a selective mutational pattern associated with tumor histology and tissue of origin [14] . It has been proposed that mutations occur more commonly in tumors derived from tissues with low proliferation rates [12] [13] [14] . Based on the analysis of 21 UBCs, a high mutation rate was proposed, but there was no clinical or pathologic information on these patients. In this paper, we provide definitive evidence on the occurrence of TERT promoter mutations in UBC. First, we show a high mutation rate (70%), which was replicated in an independent series (79%) using different assays, thus making TERT the most frequently mutated gene in UBC. Second, we show a similar mutation frequency across stages and grades, strongly suggesting that TERT mutations participate in the two major genetic pathways involved in UBC. Third, we show a distinct mutational spectrum in comparison with melanoma with a dominance of the C228T mutation. Finally, we show a lack of association with progression in NMIBC or with the development of local or distant metastases in MIBC.
The high frequency of hotspot mutations renders TERT a very attractive target for diagnosis of bladder tumors, both primary and recurrent, using body fluids such as urine or blood. We show that tumor cell detection in urine is feasible, with a sensitivity of 62% at initial diagnosis and 42% at recurrence. For urine diagnostics during surveillance, the patients were not stratified for mutation status of the primary tumor; we expect that when this is performed, sensitivity of detection of recurrent UBC will increase. Accordingly, TERT mutation was assayed concomitantly in tumor tissue and urine in 31 cases: TERT was concordant in 26 cases (19 mutated, 7 wild type), one tumor harbored a C242T mutation not assessable by the SNaPshot assay, and four mutations were detected in urine but not in tumor samples. We show that TERT mutation detection has a higher sensitivity than FGFR3 mutation for tumor cell detection in urine, and assays of both TERT and FGFR3 mutations might have improved sensitivity, though the difference was not statistically significant in our study. By contrast, TERT mutations may have a lower specificity than FGFR3 mutations, as four mutations were detected in 39 urine samples from patients without cancer and in 58 of 218 of patients in clinical remission. In this group, we cannot distinguish reduced specificity from higher leadtime bias in detection of tumor relapse. Larger, welldesigned, prospective studies are required to establish the clinical usefulness of mutation detection in urine. As previous reports have proposed TERT expression or activity assessment in urine as a tool to detect recurrence, it will be of high interest to compare TERT mutation with them and with other candidate biomarkers in future studies [17, 18] .
Several observations support the notion that TERT somatic mutations are an early event in urothelial carcinogenesis, including their occurrence in a small fraction of subjects without UBC, their presence in tumors of both the papillary and invasive pathways, and the low level of intraindividual heterogeneity when multiple tumor regions were analyzed. UBC cell lines are also very frequently mutated, and we noticed that most of the mutant ones lacked the wild-type allele. These observations also suggest that mutant cells may display a growth advantage over wild-type cells.
The mechanisms through which TERT promoter mutations contribute to UBC and other tumors remain to be determined. One possibility is that the acquisition of new, putative transcription binding sites leads to altered regulation of gene expression, as previously proposed, and also suggested by our bioinformatics analysis using the DNA-binding factor database JASPAR. However, we failed to find a significant association between TERT mutation and expression. This could be explained by alternative mechanisms of TERT upregulation in wild-type tumors, also leading to TERT overexpression, or by the participation of TERT mutations in additional biologic processes.
Given its reverse transcriptase activity, telomerase is a potential therapeutic target. Recent developments suggest that azidothymidine (AZT), an inhibitor of HIV reverse transcriptase, also inhibits telomerase. Hence, it is conceivable that AZT or other telomerase inhibitors may suppress the growth of UBC overexpressing the enzyme [19] .
One of the limitations of our work is the retrospective nature of the cohorts used for the outcome analysis, even though our results do not make positive claims. Another is the lack of comparison for urine-based diagnostic assays between TERT mutation, cytology, and other biomarkers. However, the high frequency of these mutations in urine reported herein provides evidence for future prospective and comparative studies. Overall, the novelty of TERT mutation in UBC is strengthened by the independent analysis that we performed in two different centers.
Conclusions
Mutations in the promoter of the TERT gene are the most frequent somatic mutations in tumors of the urinary bladder. Mutations occur with similar frequency, regardless of stage or grade, and are not associated with clinical outcome. TERT mutation assays may be used for tumor cell detection in urine and TERT may be a therapeutic target.
